Citations

Clear

114 citation(s) found for "Scott, Michael".

ASHP and ASHP Foundation Pharmacy Forecast 2025: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
Hoffman, James M. , Tichy, Eric M. , Shea, Suzanne, Sanborn, Michael, Fox, Erin R. , Torrise, Virginia, Abourjaily, Paul , Cunningham, Francesca , Schweitzer, Pamela, Nelson, Scott D. , Stump, Lisa S, Castro, Harvey, Nesbit, Todd, Scott, Christopher M., Tichy, Eric, DiPiro, Joseph T. , Shea, Suzanne, Hung, Anna , Watanabe, Jonathan Hirohiko , Stump, Lisa S. , Castro, Harvey

Mayo Clinic

American Journal of Health-System Pharmacy | September 27, 2024 | Volume: 82 | Issue: 2 | Pages: 17-47

10.1093/ajhp/zxae280 | PMID 39657700 Get It

Abstract Purpose The 2025 ASHP Pharmacy Forecast report is written to identify and contextualize emerging trends that will influence healthcare, health systems, and the pharmacy profession. It provides recommendations to inform strategic planning that should prompt action by pharmacists and health-system leaders. Methods Drawing on the “wisdom of crowds” concept, a survey was constructed by an advisory committee with 6 themes, each with 7 focused statements and a seventh theme on preparedness (54 survey items in total). A survey panel of 321 pharmacy leaders was purposefully designed to capture opinions from a wide range of pharmacists across the United States. Panelists were asked to consider the likelihood of the statements occurring in the next 5 years as being likely, somewhat likely, somewhat unlikely, or very unlikely to occur. Forecast panelists also assessed health systems’ preparedness (from very unprepared to very prepared) for 12 of the statements. Results The 6 survey themes identified were The Business of Healthcare: Challenges in Health-System Pharmacy, Managing Ultra-High-Cost Drugs, Addressing the Gap in Primary Care, Whole Person Health, Navigating Generative Artificial Intelligence: Opportunity and Risk, and Stabilizing the Pharmacy Workforce. The survey was completed by 269 respondents, yielding an 84% response rate. Descriptive statistics of the survey results were provided to chapter authors to inform commentary and strategic recommendations for each theme. Conclusion The Pharmacy Forecast provides insights on large-scale, long-term trends that will influence healthcare and the pharmacy profession over the years ahead. Insight from the report can stimulate strategic thinking and provides a starting point to proactively position leaders, their teams, and departments for potential future trends.
One-Year Outcomes of Transseptal Mitral Valve-in-Valve in Intermediate Surgical Risk Patients
Malaisrie, S. Chris , Guerrero, Mayra , Davidson, Charles J. , Shah, Pinak , Kaneko, Tsuyoshi , Poon, Karl, Levisay, Justin , Xiao, Yu , Pîbarot, Philippe , Leon, Martin B. , Mack, Michael J. , Zajarías, Alan , Investigators, on behalf of the PARTNER 3 Mitral Valve-in-Valve Study, Davidson, Charles J. , Abizaid, Alexandre , Shah, Pinak , Kaneko, Tsuyoshi , Levisay, Justin , Yu, Xiao , Pibarot, Phillippe , Hahn, Rebecca T , Mack, Michael J , Guerrero, Mayra E , Williams, Mathew , Brito, Fábio Sândoli de , Abizaid, Alexandre , Blanke, Philipp , Investigators, on behalf of the PARTNER 3 Mitral Valve-in-Valve Study

Mayo Clinic

Circulation: Cardiovascular Interventions | July 22, 2024 | Volume: 17 | Issue: 8 | Pages: No page available

10.1161/circinterventions.123.013782 | PMID 39034924 Get It

BACKGROUND: Transcatheter mitral valve-in-valve replacement offers a less-invasive alternative for high-risk patients with bioprosthetic valve failure. Limited experience exists in intermediate-risk patients. We aim to evaluate 1-year outcomes of the PARTNER 3 mitral valve-in-valve study. METHODS: This prospective, single-arm, multicenter study enrolled symptomatic patients with a failing mitral bioprosthesis demonstrating greater than or equal to moderate stenosis and regurgitation and Society of Thoracic Surgeons score ≥3% and <8%. A balloon-expandable transcatheter heart valve (SAPIEN 3, Edwards Lifesciences) was used via a transeptal approach. The primary end point was the composite of all-cause mortality and stroke at 1 year. RESULTS: A total of 50 patients from 12 sites underwent mitral valve-in-valve from 2018 to 2021. The mean age was 70.1±9.7 years, mean Society of Thoracic Surgeons score was 4.1%±1.6%, and 54% were female. There were no primary end point events (mortality or stroke) through 1 year, and no left-ventricular outflow tract obstruction, endocarditis, or mitral valve reintervention was reported. Six patients (12%) required rehospitalization, including heart failure (n=2), minor procedural side effects (n=2), and valve thrombosis (n=2; both resolved with anticoagulation). An additional valve thrombosis was associated with no significant clinical sequelae. From baseline to 1 year, all subjects with available data had none/trace or mild (grade 1+) mitral regurgitation and the New York Heart Association class improved in 87.2% (41/47) of patients. CONCLUSIONS: Mitral valve-in-valve with a balloon-expandable valve via transseptal approach in intermediate-risk patients was associated with improved symptoms and quality of life, adequate transcatheter valve performance, and no mortality or stroke at 1-year follow-up. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03193801.
Determinants of successful ictal SPECT injection in phase 1 epilepsy presurgical evaluation: Findings from the pediatric epilepsy research consortium surgery database project
Joshi, Charuta , Singh, Rani K. , Liu, Gang , Karakas, Cemal , Ciliberto, Michael A. , Eschbach, Krista , Perry, Μ. Scott , Shrey, Daniel W. , Morphew, Tricia , Ostendorf, Adam P. , Reddy, Shilpa B. , McCormack, Michael J., Karia, Samir , Nangia, Shrishti, Workgroup, the PERC Surgery, Perry, Michael Scott , Wong-Kisiel, Lily, Eschbach, Krista , Karakas, Cemal , Liu, Gang, Wong‐Kisiel, Lily C. , Workgroup, the PERC Surgery

Mayo Clinic

Epilepsia Open | June 7, 2024 | Volume: 9 | Issue: 4 | Pages: 1467-1479

10.1002/epi4.12986 | PMID 38845472 Get It

AbstractObjectivesThe main goal of presurgical evaluation in drug‐resistant focal epilepsy is to identify a seizure onset zone (SOZ). Of the noninvasive, yet resource‐intensive tests available, ictal single‐photon emission computed tomography (SPECT) aids SOZ localization by measuring focal increases in blood flow within the SOZ via intravenous peri‐ictal radionuclide administration. Recent studies indicate that geographic and center‐specific factors impact utilization of these diagnostic procedures. Our study analyzed successful ictal SPECT acquisition (defined as peri‐ictal injection during inpatient admission) using surgery‐related data from the Pediatric Epilepsy Research Consortium (PERC) surgery database. We hypothesized that a high seizure burden, longer duration of video EEG monitoring (VEEG), and more center‐specific hours of SPECT availability would increase the likelihood of successful ictal SPECT.MethodsWe identified study participants (≤18 years of age) who underwent SPECT as part of their phase 1 VEEG from January 2018 to June 2022. We assessed association between ictal SPECT outcomes (success vs. failure) and variables including patient demographics, epilepsy history, and center‐specific SPECT practices.ResultsPhase 1 VEEG monitoring with ictal SPECT injection was planned in 297 participants and successful in 255 participants (85.86%). On multivariable analysis, the likelihood of a successful SPECT injection was higher in patients of non‐Hispanic ethnicity (p = 0.040), shorter duration VEEG (p = 0.004), and higher hours of available SPECT services (p < 0.001). Higher seizure frequency (p = 0.033) was significant only in bivariate analysis. Patients treated at centers with more operational hours were more likely to experience pre‐admission protocols prior to VEEG (p = 0.002).SignificanceThere is inter‐center variability in protocols and SPECT acquisition capabilities. Shorter duration of EEG monitoring, non‐Hispanic ethnicity (when on private insurance), extended operational hours of nuclear medicine as noted on multivariate analysis and higher seizure frequency in bivariate analysis are strongly associated with successful ictal SPECT injection.Plain Language SummaryIn pediatric patients with drug‐resistant epilepsy, single‐photon emission computed tomography (SPECT) scans can be helpful in localizing seizure onset zone. However, due to many logistical challenges described below, which include not only the half‐life of the technetium isotope used to inject intravenously during a seizure (called the ictal SPECT scan) but also available nuclear scanner time in addition to the unpredictability of seizures, obtaining an ictal SPECT during a planned elective inpatient hospital stay is not guaranteed. Thus, as healthcare costs increase, planning a prolonged hospital stay during which an ictal SPECT scan is not feasible is not optimal. We leveraged our prospective surgery database to look at center‐specific factors and patient‐specific factors associated with an ictal SPECT injection in the first, pediatric‐focussed, large‐scale, multicenter, prospective, SPECT feasibility study. We found that longer availability of the scanner is the most important center‐specific factor in assuring ictal SPECT injection. Although seizure frequency is an important patient‐specific factor on bivariate analysis, this factor lost statistical significance when other factors like patient insurance status and video EEG duration were also considered in our multivariable logistical model.
Global modified‐Delphi consensus on comorbidities and prognosis of SCN8A‐related epilepsy and/or neurodevelopmental disorders
Conecker, Gabrielle , Xia, Maya , Hecker, JayEtta , Achkar, Christelle Moufawad El , Cukiert, Cristine Mella , Devries, Seth , Donner, Elizabeth , Fitzgerald, Mark P. , Hammer, Michael F. , Hegde, Anaita , Hu, Chunhui , Luo, Tian , Kooistra, T., Waldrop, Kayla, Youngquist, J. Tyler, Zhang, Dennis, Perry, Μ. Scott , Fitzgerald, Mark , Gardella, Elena , Hammer, Michael , Hu, Chunhui , Kato, Mitsuhiro , Schreiber, John R. , Oudin, Madeleine , Wirrell, Elaine C , Perry, Michael Scott , Gardella, Elena , Wang, Yi , Kooistra, Tammy, Waldrop, Kayla, Youngquist, J. Tyler, Wirrell, Elaine

Mayo Clinic

Epilepsia | May 28, 2024 | Volume: 65 | Issue: 8 | Pages: 2308-2321

10.1111/epi.17991 | PMID 38802989 Get It

AbstractObjectivesWe aimed to develop consensus on comorbidities (frequency, severity, and prognosis) and overall outcomes in epilepsy, development, and cognition for the five phenotypes of SCN8A‐related disorders.MethodsA core panel consisting of 13 clinicians, 1 researcher, and 6 caregivers was formed and split into three workgroups. One group focused on comorbidities and prognosis. All groups performed a literature review and developed questions for use in a modified‐Delphi process. Twenty‐eight clinicians, one researcher, and 13 caregivers from 16 countries participated in three rounds of the modified‐Delphi process. Consensus was defined as follows: strong consensus ≥80% fully agree; moderate consensus ≥80% fully or partially agree, <10% disagree; and modest consensus 67%–79% fully or partially agree, <10% disagree.ResultsConsensus was reached on the presence of 14 comorbidities in patients with Severe Developmental and Epileptic Encephalopathy (Severe DEE) spanning non‐seizure neurological disorders and other organ systems; impacts were mostly severe and unlikely to improve or resolve. Across Mild/Moderate Developmental and Epileptic Encephalopathy (Mild/Moderate DEE), Neurodevelopmental Delay with Generalized Epilepsy (NDDwGE), and NDD without Epilepsy (NDDwoE) phenotypes, cognitive and sleep‐related comorbidities as well as fine and gross motor delays may be present but are less severe and more likely to improve compared to Severe DEE. There was no consensus on comorbidities in the SeL(F)IE phenotype but strong conesensus that seizures would largely resolve. Seizure freedom is rare in patients with Severe DEE but may occur in some with Mild/Moderate DEE and NDDwGE.SignificanceSignificant comorbidities are present in most phenotypes of SCN8A‐related disorders but are most severe and pervasive in the Severe DEE phenotype. We hope that this work will improve recognition, early intervention, and long‐term management for patients with these comorbidities and provide the basis for future evidence‐based studies on optimal treatments of SCN8A‐related disorders. Identifying the prognosis of patients with SCN8A‐related disorders will also improve care and quality‐of‐life for patients and their caregivers.
Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A‐related epilepsy and/or neurodevelopmental disorders
Conecker, Gabrielle , Xia, Maya , Hecker, JayEtta , Achkar, Christelle Moufawad El , Cukiert, Cristine Mella , Devries, Seth , Donner, Elizabeth , Fitzgerald, Mark P. , Gardella, Elena , Hammer, Michael F. , Hegde, Anaita , Hu, Chunhui , Luo, Tian , Kooistra, T., Waldrop, Kayla, Youngquist, J. Tyler, Zhang, Dennis, Perry, Μ. Scott , Hammer, Michael , Kato, Mitsuhiro , Schreiber, John R. , Oudin, Madeleine , Wirrell, Elaine C , Perry, Michael Scott , Fitzgerald, Mark , Gardella, Elena , Wang, Yi , Kooistra, Tammy, Wirrell, Elaine

Mayo Clinic

Epilepsia | May 28, 2024 | Volume: 65 | Issue: 8 | Pages: 2322-2338

10.1111/epi.17992 | PMID 38802994 Get It

AbstractObjectiveWe aimed to develop consensus for diagnosis/management of SCN8A‐related disorders. Utilizing a modified Delphi process, a global cohort of experienced clinicians and caregivers provided input on diagnosis, phenotypes, treatment, and management of SCN8A‐related disorders.MethodsA Core Panel (13 clinicians, one researcher, six caregivers), divided into three subgroups (diagnosis/phenotypes, treatment, comorbidities/prognosis), performed a literature review and developed questions for the modified Delphi process. Twenty‐eight expert clinicians, one researcher, and 13 caregivers from 16 countries participated in the subsequent three survey rounds. We defined consensus as follows: strong consensus, ≥80% fully agree; moderate consensus, ≥80% fully/partially agree, <10% disagree; and modest consensus, 67%–79% fully/partially agree, <10% disagree.ResultsEarly diagnosis is important for long‐term clinical outcomes in SCN8A‐related disorders. There are five phenotypes: three with early seizure onset (severe developmental and epileptic encephalopathy [DEE], mild/moderate DEE, self‐limited (familial) infantile epilepsy [SeL(F)IE]) and two with later/no seizure onset (neurodevelopmental delay with generalized epilepsy [NDDwGE], NDD without epilepsy [NDDwoE]). Caregivers represented six patients with severe DEE, five mild/moderate DEE, one NDDwGE, and one NDDwoE. Phenotypes vary by age at seizures/developmental delay onset, seizure type, electroencephalographic/magnetic resonance imaging findings, and first‐line treatment. Gain of function (GOF) versus loss of function (LOF) is valuable for informing treatment. Sodium channel blockers are optimal first‐line treatment for GOF, severe DEE, mild/moderate DEE, and SeL(F)IE; levetiracetam is relatively contraindicated in GOF patients. First‐line treatment for NDDwGE is valproate, ethosuximide, or lamotrigine; sodium channel blockers are relatively contraindicated in LOF patients.SignificanceThis is the first‐ever global consensus for the diagnosis and treatment of SCN8A‐related disorders. This consensus will reduce knowledge gaps in disease recognition and inform preferred treatment across this heterogeneous disorder. Consensus of this type allows more clinicians to provide evidence‐based care and empowers SCN8A families to advocate for their children.
Effect of an increased dose of intrathecal fentanyl on cesarean delivery anesthesia at a Texas level IV maternal care center
Vacula, Madeline, Sharpe, Emily E. , Hofkamp, Michael P. , Hofkamp, Michael P , Sharpe, Emily E , Hammonds, Kendall A. P.

Mayo Clinic

Baylor University Medical Center Proceedings | May 17, 2024 | Volume: 37 | Issue: 4 | Pages: 592-596

10.1080/08998280.2024.2349985 | PMID 38910802 Get It

Abstract 14711: Effect of Release of the First Pediatric Appropriate Use Criteria on Outpatient Transthoracic Echocardiogram Ordering Practice
Sachdeva, Ritu , McCracken, Courtney , Allen, Joseph M., Benavidez, Oscar J., Campbell, Robert M, Eidem, Benjamin W., Gold, Lara, Lopez, Leo , Weiner, Rory B., Welch, Elizabeth , Kelleman, Michael Scott , Campbell, Robert M, Douglas, Pamela S. , Stern, Kenan W.D. , Lai, Wyman W.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.14711 Get It

Background: The first pediatric appropriate use criteria (PAUC) were recently published for initial outpatient transthoracic echocardiography (TTE). We sought to determine the effect of release of the PAUC on the appropriateness of TTE ordering patterns of pediatric cardiologists. Methods: Data were prospectively collected from patients having initial outpatient TTE ordered prior to (Phase I, 6 mo) and 3 months after release (Phase II, 4 mo) of PAUC. Site-investigators determined the indication of the study and assigned appropriateness rating based on the PAUC document [Appropriate (A), May Be Appropriate (M), or Rarely Appropriate (R)] or "Unclassifiable" (U). Results: A total of 4562 TTEs (2655 Phase I, 1907 Phase II) were ordered by 103 physicians at 6 sites. Overall comparison of appropriateness rating for Phase I and II showed no change in the rate for A or M, but a decline in the rate of R and increase in U. Similar results were noted when comparisons were made for physicians that ordered at least 20 TTEs during each phase (N = 30/103, 29%), Table 1. There was no change in any appropriateness rating at 3 sites, a decline in R at 2, an increase in A at 1, and an increase in U at 2 sites. Overall and site-specific comparisons of rate of R TTEs are shown in Fig 1. Conclusions: The release of PAUC document had only a small impact on physician ordering behavior for initial TTEs, including a small decrease in R. Overall, these data suggest that more focused interventions are required to fully implement guideline recommendations and improve the appropriate use of pediatric TTE. This information should be helpful in designing educational interventions to reduce the rate of TTEs ordered for R indications.
γ‐Glutamyl Transferase and Long‐Term Survival in the SYNTAXES Trial: Is It Just the Liver?
Ninomiya, Kai, Serruys, Patrick W. , Garg, Scot , Kotoku, Nozomi , Masuda, Shinichiro , Kappetein, A. Pieter , Mack, Michael J. , Holmes, David R. , Davierwala, Piroze , Mohr, Friedrich W., Thuijs, Daniel J.F.M. , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival (SYNTAXES), Kappetein, Arie Pieter , Mack, Michael J , Holmes, David R , Thuijs, Daniel J F M , Onuma, Yoshinobu , Serruys, Patrick W , Garg, Scot , Kageyama, Shigetaka , Revaiah, Pruthvi C. , O’Leary, Neil , Investigators, for the SYNTAX Extended Survival (SYNTAXES)

Mayo Clinic

Journal of the American Heart Association | April 2, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.032276 | PMID 38563386 Get It

Background Recently, machine learning algorithms have identified preprocedural γ‐glutamyl transferase (GGT) as a significant predictor of long‐term mortality after coronary revascularization in the SYNTAX (Synergy Between PCI [Percutaneous Coronary Intervention] With Taxus and Cardiac Surgery) trial. The aim of the present study is to investigate the impact of preprocedural GGT on 10‐year all‐cause mortality in patients with complex coronary artery disease after revascularization. Methods and Results The SYNTAX trial was a randomized trial comparing PCI with coronary artery bypass grafting in 1800 patients with complex coronary artery disease. The present report is a post hoc subanalysis of the SYNTAXES (Synergy Between PCI With Taxus and Cardiac Surgery Extended Survival) trial, an investigator‐driven extended 10‐year follow‐up of the SYNTAX trial. The association between preprocedural GGT and 10‐year all‐cause mortality was investigated. The mean values of GGT for men and women were 43.5 (SD, 48.5) and 36.4 (SD, 46.1) U/L, respectively. In multivariable Cox regression models adjusted by traditional risk factors, GGT was an independent predictor for all‐cause death at 10‐year follow‐up, and each SD increase in log‐GGT was associated with a 1.24‐fold risk of all cause death at 10‐year follow‐up (95% CI, 1.10–1.40). According to previously reported sex‐related GGT thresholds, patients with higher GGT level had a 1.74‐fold risk of all‐cause death at 10‐year follow‐up (95% CI, 1.32–2.29) compared with patients with lower GGT level. Conclusions Preprocedural GGT is an independent predictor of 10‐year mortality after coronary revascularization in patients with complex coronary artery disease. In patients with elevated GGT, strong secondary prevention may be required after revascularization and must be studied prospectively. Registration URL: https://clinicaltrials.gov/study/NCT03417050 .
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Brahmania, Mayur , Kuo, Alexander , Tapper, Elliot B. , Völk, Michael , Vittorio, Jennifer , Ghabril, Marwan , Morgan, Timothy R. , Kanwal, Fasiha , Parikh, Neehar D. , Mehta, Shivang , Goldberg, David S. , Duarte‐Rojo, Andrés , Paredes, Angelo H. , Sahota, Amandeep , McElroy, Lisa M. , Thomas, Charlie, Aslam, Saima , Ramakrishnan, Sudha , Flynn, Mary M. , Volk, Michael L , Vittorio, Jennifer M , Mehta, Shivang , Winder, Scott , Im, Gene , Goldberg, David , Lai, Jennifer , Duarte-Rojo, Andres , Paredes, Angelo H , Patel, Arpan , Sahota, Amandeep , McElroy, Lisa M , Wall, Anji E , Malinis, Maricar , Aslam, Saima , Simonetto, Douglas A , Ufere, Nneka N , Ramakrishnan, Sudha , Ibrahim, Yasmin , Asrani, Sumeet K , Serper, Marina , Ghabril, Marwan S , Parikh, Neehar D , Kanwal, Fasiha , Martin, Paul B. , Winder, Gerald Scott , Lai, Jennifer C. , Patel, Arpan , Wall, Anji , Simonetto, Douglas A. , Asrani, Sumeet K. , Serper, Marina

Mayo Clinic

Hepatology | March 27, 2024 | Volume: 80 | Issue: 3 | Pages: 742-753

10.1097/hep.0000000000000870 | PMID 38536021 Get It

The liver transplantation (LT) evaluation and waitlisting process is subject to variations in care that can impede quality. The American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) developed quality measures and patient-reported experience measures along the continuum of pre-LT care to reduce care variation and guide patient-centered care. Following a systematic literature review, candidate pre-LT measures were grouped into 4 phases of care: referral, evaluation and waitlisting, waitlist management, and organ acceptance. A modified Delphi panel with content expertise in hepatology, transplant surgery, psychiatry, transplant infectious disease, palliative care, and social work selected the final set. Candidate patient-reported experience measures spanned domains of cognitive health, emotional health, social well-being, and understanding the LT process. Of the 71 candidate measures, 41 were selected: 9 for referral; 20 for evaluation and waitlisting; 7 for waitlist management; and 5 for organ acceptance. A total of 14 were related to structure, 17 were process measures, and 10 were outcome measures that focused on elements not typically measured in routine care. Among the patient-reported experience measures, candidates of LT rated items from understanding the LT process domain as the most important. The proposed pre-LT measures provide a framework for quality improvement and care standardization among candidates of LT. Select measures apply to various stakeholders such as referring practitioners in the community and LT centers. Clinically meaningful measures that are distinct from those used for regulatory transplant reporting may facilitate local quality improvement initiatives to improve access and quality of care.
Patient characteristics associated with acute kidney injury following coronary angiography
Knott, Jonathan D , Engheta, Michael , Michel, Jeffery, Mixon, Timothy A. , Widmer, R. Jay , Knott, Jonathan , Widmer, Robert Jay

Mayo Clinic

Baylor University Medical Center Proceedings | January 17, 2024 | Volume: 37 | Issue: 3 | Pages: 382-387

10.1080/08998280.2024.2301903 | PMID 38628321 Get It